公开(公告)号：US20180264010A1

公开(公告)日：2018-09-20

申请号：US15542187

申请日：2016-01-15

Applicant: DSM IP ASSETS B.V.

Inventor： Pietro CELI ,  Shuen Ei CHEN ,  Thau Kiong CHUNG

IPC: A61K31/593 ,  A23K50/10 ,  A23K50/75 ,  A23K20/174 ,  A23K20/179 ,  A23K20/20 ,  A61K31/375 ,  A61K31/355 ,  A61K31/122 ,  A61P15/00 ,  A61P3/08 ,  A61P3/06 ,  A61P39/00

CPC classification number: A23K20/174 ,  A23K20/179 ,  A23K20/30 ,  A23K50/10 ,  A23K50/42 ,  A23K50/48 ,  A23K50/75 ,  A61K9/0056 ,  A61K31/015 ,  A61K31/122 ,  A61K31/197 ,  A61K31/355 ,  A61K31/375 ,  A61K31/4188 ,  A61K31/455 ,  A61K31/519 ,  A61K31/525 ,  A61K31/593 ,  A61K31/675 ,  A61K33/04 ,  A61K33/26 ,  A61K33/32 ,  A61K33/34 ,  A61P3/06 ,  A61P3/08 ,  A61P9/00 ,  A61P15/00 ,  A61P15/08 ,  A61P39/00

Abstract: This invention relates to the use of the combination of 25-hydroxyvitamin D3 (“25-OH D3”) and antioxidants/anti-inflammatories (ascorbic acid, vitamin E and at least one carotenoid) to make a pharmaceutical, nutraceutical or food supplement which can ameliorate various problems observed in bovines connected cystic ovarian disease, or increasing 17-β estradiol levels. Feed and premixes containing the 25-OH D3 and antioxidants/anti-inflammatories and premixes are also provided.

公开(公告)号：US20240125749A1

公开(公告)日：2024-04-18

申请号：US18554900

申请日：2022-04-06

Applicant: DSM IP ASSETS B.V.

Inventor： Pietro CELI ,  James COVINGTON ,  Nicola WALKER

IPC: G01N33/00 ,  A23K20/105 ,  A23K50/10

CPC classification number: G01N33/0047 ,  A23K20/105 ,  A23K50/10

Abstract: The present invention relates to a method of increasing the volatile organic compound (VOC) emissions in a ruminant, said method comprising the administration of a methane inhibitor to said ruminant. The increase in the VOC emissions can be used for monitoring and/or quantifying the reduction of methane emanating from the digestive activities of the ruminant affected by the feeding of said methane inhibitor.

公开(公告)号：US20200376015A1

公开(公告)日：2020-12-03

申请号：US16633390

申请日：2018-07-23

Applicant: DSM IP ASSETS B.V.

Inventor： Christopher Michael BUTT ,  Pietro CELI ,  Norman SALEM

IPC: A61K31/7028 ,  A23K20/158 ,  A23K20/189 ,  A23K20/174 ,  A23K20/20 ,  A23K20/142 ,  A23K10/18 ,  A23K50/75 ,  A61P31/00

Abstract: The invention relates to methods for modulation of the gut flora and/or for supporting immune system function in animals comprising administration of one or more sophorolipids to an animal in need thereof. Animal feed compositions comprising sophorolipids are also provided.

公开(公告)号：US20230086913A1

公开(公告)日：2023-03-23

申请号：US17984770

申请日：2022-11-10

Applicant: DSM IP ASSETS B.V.

Inventor： Christopher Michael BUTT ,  Pietro CELI ,  Norman SALEM

IPC: A61K31/7028 ,  A23K20/142 ,  A23K20/158 ,  A23K20/174 ,  A23K20/189 ,  A23K20/20 ,  A23K50/75 ,  A23K10/18 ,  A61P31/00

Abstract: The invention relates to methods for modulation of the gut flora and/or for supporting immune system function in animals comprising administration of one or more sophorolipids to an animal in need thereof. Animal feed compositions comprising sophorolipids are also provided.

公开(公告)号：US20220288103A1

公开(公告)日：2022-09-15

申请号：US17271998

申请日：2019-08-28

Applicant: DSM IP ASSETS B.V.

Inventor： Maaike Johanna BRUINS ,  Sophie FEHLBAUM ,  Thanh-Van PHAM ,  Kevin PRUDENCE ,  Robert STEINERT ,  Pietro CELI ,  Gilberto LITTA ,  Estefania PEREZ CALVO ,  Wilbert SYBESMA

IPC: A61K31/714 ,  A61K31/07 ,  A61K31/525 ,  A61K31/375 ,  A61K31/593 ,  A61K31/122 ,  A61K31/519 ,  A61K31/015 ,  A61K31/51 ,  A61K31/455 ,  A61K31/197 ,  A61K31/4415 ,  A61K31/4188 ,  A61K31/202 ,  A61K31/355 ,  A61P1/14

Abstract: Various benefits to intestinal health are made by delivery of an active agent to the colon of an animal, including a human. Active ingredients include of riboflavin, vitamin A, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, β-carotene, vitamin B1, niacin, vitamin B5, vitamin B6, biotin, vitamin B12, omega-3 fatty acids and combinations thereof. Benefits include increased concentration of at least one short-chain fatty acid its salt thereof in the intestine, increased microbiome diversity in the intestine, increased beneficial bacteria in the intestine, increased the butyrate synthesis pathway in the intestine, improved barrier function of the intestine, reduced redox potential of the gut, reduced amount of gas produced in the intestine; and stimulation of intestinal immune responses.